First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU

View source ↗

Summary

The EMA recommends approval of the first histone deacetylase (HDAC) inhibitor for the treatment of multiple myeloma in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HDAC inhibitor (specific agent not named in prompt)